Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 9/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 8/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803541 | 1.00 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1ITRPV1BRD4 | |
| SCHEMBL1803543 | 1.00 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1ITRPV1BRD4 | |
| SCHEMBL17075097 | 0.79 | SIGMAR1 (0.45) | CACNA1GCACNA1HCACNA1ITRPV1BRD4 | |
| SCHEMBL1806733 | 0.79 | HTR2C (0.36) | — | |
| SCHEMBL2598180 | 0.79 | HTR2C (0.36) | — | |
| SCHEMBL1804672 | 0.76 | HRH1 (0.39) | TRPV1SIGMAR1 | |
| SCHEMBL1804674 | 0.76 | HRH1 (0.39) | TRPV1SIGMAR1 | |
| SCHEMBL1804670 | 0.76 | HRH1 (0.39) | TRPV1SIGMAR1 | |
| SCHEMBL1806367 | 0.74 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1ITRPV1BRD4 | |
| SCHEMBL1806368 | 0.74 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1ITRPV1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CACNA1G 1780/4885CACNA1H 1323/4885CACNA1I 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.